WAUKESHA, Wis. (CBS 58) -- A dream came true for a group of kids in Waukesha Tuesday. Twenty-five children from SHARP Literacy's educational program at La Casa de Esperanza elementary school each ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback